Vertex (NASDAQ: VERX) — Perfil da empresa, notícias e dados financeiros
Vertex is a biopharmaceutical company focused on transformative medicines for cystic fibrosis and serious diseases.
VERX Vertex
Perfil da empresa
Vertex
Vertex (NASDAQ:VERX) specializes in creating transformative medicines for people with serious diseases, with a focus on treating cystic fibrosis (CF). Beyond CF, Vertex is actively exploring treatments in other serious diseases through a pipeline of research and development projects. The company’s objective is to develop and commercialize these medicines with the aim of improving the lives of patients. Vertex's commitment to innovation extends to collaborations with other organizations and efforts to advance science and health care for diseases with significant unmet needs.
Resumo
Public USParticipação acionária
1978Ano de fundação
2292Funcionários
Pennsylvania, United StatesSede
Carregando mapa...
Presença global
Operações
Todos os locais
United States
Produtos e/ou serviços de Vertex
- Cystic Fibrosis Therapies: Revolutionized treatment of cystic fibrosis with a portfolio that targets the underlying cause of the disease, significantly improving patients' quality of life.
- Sickle Cell Disease and Beta Thalassemia Treatment: Developing gene-editing therapies aimed at treating these genetic disorders, potentially offering a cure or significant disease modification.
- Pain Management: An innovative approach to pain management intending to offer non-opioid, targeted treatments for acute and chronic pain, addressing a major medical need.
- Type 1 Diabetes: Engaged in research to create stem cell-derived therapies to potentially cure type 1 diabetes, aiming to replace the need for insulin injections.
- Alpha-1 Antitrypsin Deficiency (AATD): Working on treatments for AATD, a genetic disorder that can lead to significant lung disease, with the goal of addressing the root cause.
- APOL1-Mediated Kidney Disease: Focused on discovering and developing treatments for kidney diseases associated with APOL1 mutations, aiming to halt or reverse disease progression.
equipe executiva do Vertex
- Christopher David YoungCEO, President & Director
- Amanda Westphal RadcliffeCo-Owner & Independent Director
- Stefanie Westphal-Lucas ThompsonCo-Owner & Independent Director
- John R. SchwabChief Financial Officer
- Bryan T. R. RowlandSenior VP, General Counsel & Secretary
- Ray WestphalFounder
- Aneel JaeelChief Operations Officer
- Ryan J. LeibChief Accounting Officer
- Bala ChandranChief Product & Technology Officer
- Joseph J. CrivelliVice President of Investor Relations
Principais indicadores financeiros
Resultados divulgados pela Vertex, em USD.
- Cap. de mercado
- 2,4 bi
- Receita (TTM)
- 787,4 mi
- P/L
- 1480.0
- LPA (diluído, TTM)
- 0.0
- Dividend yield
- —
- Margem de lucro
- 0.4%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 748,4 mi | -7,8 mi | 7,2 mi | |
| 666,8 mi | -2,2 mi | -52,7 mi | |
| 572,4 mi | -17,5 mi | -13,1 mi | |
| 491,6 mi | -8,1 mi | -12,3 mi |